에 대한 최신 뉴스 Evaxion Biotech (NASDAQ:EVAX) 주식

EVAXION BIOTECH A/S

Evaxion Biotech

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are: EVX-01, EVX-03, and EVX-02, which are vaccine candidates being developed for the treatment of various solid cancers. In addition, the company is developing EVX-B1, EVX-B2, EVX-B3, EVX-V1, and multiple other vaccine candidates for various infectious diseases, such as cytomegalovirus, N.gonorrhoeae, bacterial pathogens, and others.

Wall Street

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

AREN

CSTM

EVAX

GDYN

GEAR

VIRX

금요일(27일) 아침 미국 주식 선물이 하락하고 있는 가운데, 오늘 투자자들의 주목을 받을 수 있는 몇 가지 주식은 다음과 같다. 콘스텔리움, 비락타 테라퓨틱스, 에바종 바이오테크, 아레나 및 그리드 다이나믹

금요일 주목해야 할 주식: 콘스텔리움, 비락타, 에바종 바이오테크, 아레나 및 그리드 다이나믹

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech AS

On Monday, May 5th, U.S. markets closed lower, ending their winning streaks, as markets reacted to Trump&#8217;s tariff on foreign films. Energy stocks lagged, Berkshire Hathaway stumbled after Buffett&#8217;s exit news, and Netflix, Amazon, and Paramount saw losses. Investors are now focused on the upcoming Fed decision amid rising inflation concerns and profit risks.
According to economic data, the ISM services PMI climbed to 51.6 in April, up from March&#8217;s nine-month low of 50.8, beating market expectations of 50.6.
Most S&amp;P 500 sectors fell, led by energy, consumer discretionary, and tech, while consumer staples edged higher.
The Dow Jones Industrial Average was down 0.24% at 41,218.83, the S&amp;P 500 declined 0.64% to 5,650.38, and the Nasdaq slid 0.74% to 17,844.24.
Related: <a target="_blank" href="https://www.benzinga.com/25/05/45214594/hollywood-tariff-push-sparked-by-trump-jon-voight-meeting-where-actor-proposed-levies-in-certain-limited-circumst" rel="noreferrer noopener">Hollywood Tariff Push Sparked By Trump-Jon Voight Meeting Where Actor Proposed Levies In &#8216;Certain Limited Circumstances:&#8217; Report</a>
Asia Markets Today
<ul>
<li>Japan&#8217;s market closed for the Greenery Day holiday.</li>
<li>On Tuesday, Australia&#8217;s S&amp;P/ASX 200 declined 0.08%, ending the session at 8,151.40, led by losses in the Healthcare, Consumer Staples, and Financials sectors.</li>
<li>India&#8217;s Nifty 50 was down 0.28% at 24,391.85, and Nifty 500 fell 1.03% to 24,391.85.</li>
<li>China&#8217;s Shanghai Composite gained 1.13% to 3,316.11, and Shanghai Shenzhen CSI 300 was up 1.01% to 3,808.54.</li>
<li>Hong Kong&#8217;s Hang Seng closed the session 0.70% higher at 22,662.71.</li>
</ul>
Eurozone at 05:45 AM ET
<ul>
<li>The European STOXX 50 index was down 0.90%.</li>
<li>Germany&#8217;s DAX index declined 1.22%.</li>
<li>France&#8217;s CAC 40 slid 0.70%.</li>
<li>The U.K.&#8217;s FTSE 100 index traded lower by 0.18%.</li>
</ul>
Commodities at 05:45 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 2.89% at $58.78/bbl, and Brent was up 2.86% at $61.95/bbl.</li>
<li>Oil rebounded after six declines, lifted by bargain hunting, China&#8217;s return, and technical factors, despite lingering concerns over rising OPEC+ supply and global demand.</li>
<li>Natural Gas gained 1.97% to $3.621.</li>
<li>Gold was trading higher by 2.06% at $3,390.89, Silver was up 2.47% to $33.275, and Copper rose 0.04% to $4.7013.</li>
</ul>
U.S. Futures at 05:45 AM ET
Dow futures were down 0.70%, S&amp;P 500 futures declined 0.81%, and Nasdaq 100 futures fell 1.12%.
Forex at 05:45 AM ET
<ul>
<li>The U.S. Dollar Index fell 0.02% to 99.97, USD/JPY was down 0.26% to 143.31, and USD/AUD gained 0.36% to 1.5515.</li>
<li>The U.S. dollar slipped as investors grew cautious over Trump&#8217;s trade policies and awaited the Fed decision.</li>
</ul>
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Markets Mixed, Europe Slips, Gold Nears $3,400 Again - Global Markets Today While US Slept

General

OPAD

Offerpad Partners With Auction.com For Real Estate Services

Offerings

FCUV

Focus Universal Announced Securities Purchase Agreement With Alumni Capital For Sale Of 1M Common Stock Shares

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, "Cyclacel" or the "Company"))) today announced that it entered into an Exchange Agreement with FITTERS Diversified Berhad (9318.KL; "FITTERS"), an investment holding company engaged, through its subsidiaries, in the business of the sale of fire safety materials, equipment and fire prevention systems, "Waste-To-Resource" services and real estate development and construction.
Pursuant to the Exchange Agreement, all of the ordinary shares of FITTERS' subsidiary, Fitters Sdn. Bhd., a Malaysia-based private limited company ("Fitters Sub") shall be exchanged for common stock, par value $0.001, of Cyclacel (the "Purchaser Stock"), and Fitters Sub shall be continuing as a wholly-owned subsidiary of Cyclacel (the "Transaction"). As part of the Transaction, Cyclacel shall issue an amount of Purchaser Stock equal to 19.99% percent, which percentage may be subject to adjustment, of the issued and outstanding shares of Purchaser Stock as of the closing date to FITTERS. At the closing, it is expected that Cyclacel stockholders will own approximately 80.01% of the combined company.

CYCC

CYCCP

Cyclacel Pharmaceuticals Enters Exchange Agreement To Make FITTERS' Subsidiary, Fitters Sdn. Bhd., Its Wholly-Owned subsidiary

Sequans Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 31.43 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $8.05 million which missed the analyst consensus estimate of $8.50 million by 5.25 percent. This is a 33.63 percent increase over sales of $6.03 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

SQNS

Sequans Communications Q1 Adj. EPS $(0.24) Beats $(0.26) Estimate, Sales $8.05M Miss $8.50M Estimate

Compass Point analyst Joe Flynn downgrades MARA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) from Neutral to Sell and lowers the price target from $25 to $9.5.

Downgrades

Price Target

Analyst Ratings

MARA

Compass Point Downgrades MARA Holdings to Sell, Lowers Price Target to $9.5

Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) reported quarterly earnings of $2.25 per share which beat the analyst consensus estimate of $2.22 by 1.35 percent. This is a 1.81 percent increase over earnings of $2.21 per share from the same period last year. The company reported quarterly sales of $661.71 million which beat the analyst consensus estimate of $654.76 million by 1.06 percent. This is a 3.90 percent increase over sales of $636.84 million the same period last year.

Waters Q1 Adj. EPS $2.25 Beats $2.22 Estimate, Sales $661.71M Beat $654.76M Estimate

Tutor Perini Subsidiary Fisk Electric Bags Electrical Services Contract For The New West Tower At Cook Children's Medical Center In Texas

Ingredion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGR#NYSE">INGR</a>) raises FY2025 Adj EPS guidance from $10.75-$11.55 to $10.90-$11.60 vs $11.03 analyst estimate..

Guidance

INGR

Ingredion Raises FY2025 Adj EPS Guidance From $10.75-$11.55 To $10.90-$11.60 vs $11.03 Est

Avient (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVNT#NYSE">AVNT</a>) is looking for Q2 Adj EPS of $0.79 vs $0.79 analyst estimate..

AVNT

Avient Sees Q2 Adj EPS $0.79 vs $0.79 Est

Tech

LUMN

Lumen To Collaborate With IBM To Develop Enterprise-Grade AI Solutions At The Edge

Avient (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVNT#NYSE">AVNT</a>) affirms FY2025 Adj EPS guidance from $2.70-$2.94 to $2.70-$2.94 vs $2.78 analyst estimate..

Avient Affirms FY2025 Adj EPS Guidance of $2.70-$2.94 vs $2.78 Est

Knife River Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNF#NYSE">KNF</a>) raises FY2025 sales outlook from $3.00 billion-$3.20 billion to $3.25 billion-$3.45 billion vs $3.12 billion estimate.

Knife River Holding Raises FY2025 Sales Guidance from $3.00B-$3.20B to $3.25B-$3.45B vs $3.12B Est

Avient (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVNT#NYSE">AVNT</a>) reported quarterly earnings of $0.76 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $826.60 million which missed the analyst consensus estimate of $827.10 million by 0.06 percent. This is a 0.29 percent decrease over sales of $829.00 million the same period last year.

Avient Q1 Adj. EPS $0.76, Inline, Sales $826.60M Miss $827.10M Estimate

Knife River Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNF#NYSE">KNF</a>) reported quarterly losses of $(1.21) per share which missed the analyst consensus estimate of $(0.92) by 31.52 percent. This is a 44.05 percent decrease over losses of $(0.84) per share from the same period last year. The company reported quarterly sales of $353.50 million which beat the analyst consensus estimate of $338.82 million by 4.33 percent. This is a 7.25 percent increase over sales of $329.60 million the same period last year.

Knife River Holding Q1 EPS $(1.21) Misses $(0.92) Estimate, Sales $353.50M Beat $338.82M Estimate

Ingredion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGR#NYSE">INGR</a>) reported quarterly earnings of $2.97 per share which beat the analyst consensus estimate of $2.41 by 23.24 percent. This is a 42.79 percent increase over earnings of $2.08 per share from the same period last year. The company reported quarterly sales of $1.81 billion which missed the analyst consensus estimate of $1.84 billion by 1.37 percent. This is a 3.67 percent decrease over sales of $1.88 billion the same period last year.

Ingredion Q1 Adj. EPS $2.97 Beats $2.41 Estimate, Sales $1.81B Miss $1.84B Estimate

Health Care

IDYA

IDEAYA Biosciences Receives US FDA IND-Clearance For The Initiation Of A Phase 1 Clinical Trial in Solid Tumors

Sequans Communications Sees Preliminary Q1 Revenue $8.1M, Non-IFRS EPS $(0.24)

Sequans Communications Sees Q2 Sales $8.000M-$9.000M vs $8.90M Est

LIND

Lindblad Expeditions Inks Multi-Year Charter 0Agreement With Transcend Cruises For European River Expeditions

Press Releases

Evaxion announces closing of $10.8 million public offering

Peraso Inc. (NASDAQ: PRSO) Rides Military AI Boom as Defense Spending Surges – More Stocks Inside

Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Evaxion to present at numerous upcoming conferences

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Evaxion announces business update and full year 2024 financial results

Evaxion to present at World Vaccine Congress

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

GSIT

IVVD

KAPA

PRSO

QNTM

Abpro Hldgs

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Ainos

Aprea Therapeutics

BioCardia

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

HCW Biologics

iBio

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

PharmaCyte Biotech

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Turnstone Biologics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

XTL Biopharmaceuticals

HC Wainwright & Co.

Lake Street

Ladenburg Thalmann

Oppenheimer

금요일(27일) 아침 미국 주식 선물이 하락하고 있는 가운데, 오늘 투자자들의 주목을 받을 수 있는 몇 가지 주식은 다음과 같다.
1. 콘스텔리움 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSTM#NYSE">CSTM</a>)
콘스텔리움은 보통주 공모를 발표했다. 이로 인해 시간외 거래에서 3.4% 하락한 10.00달러에 거래되었다.
2. 비락타 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>)
비락타 이사회가 폭넓은 전략적 대안 모색 절차를 시작했다고 발표했다. 현재 진행 중인 재발성/불응성 EBV + 림프종 환자를 대상으로 한 나나-발(Nana-val)의 중추적인 임상 2상 시험을 종료할 계획이라고도 밝혔다. 시간외 거래에서 13.9% 하락한 0.2040달러를 기록했다.
3. 에바종 바이오테크 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>)
에바종은 임질균(Neisseria gonorrhoeae)을 표적으로 하는 백신에 대한 특허를 출원했다. 주가는 시간외 거래에서 104.5% 상승한 1.73달러를 기록했다.
자세한 내용은 <a href="https://www.benzinga.com/premarket/">프리마켓 커버리지</a>를 확인하세요.
4. 아레나 그룹 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREN#NASDAQ">AREN</a>)
아메리카증권거래소(NYSE American)가 아레나 그룹의 컴플라이언스 계획을 승인했다고 발표했다. 주식은 시간외 거래에서 17.6% 상승한 1.67달러를 기록했다.
5. 그리드 다이나믹 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDYN#NASDAQ">GDYN</a>)
그리드 다이나믹은 1월 2일(목) 개장 전 S&amp;P 스몰캡 600 지수에서 레벨리스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEAR#NYSE">GEAR</a>)를 대체할 예정이다. 그리드 다이나믹 주가는 시간외 거래에서 9.7% 상승한 23.11달러를 기록했다.
사진 출처: Wikimedia
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Evaxion Biotech

뉴스

에 대한 최신 뉴스 Evaxion Biotech (NASDAQ:EVAX) 주식

금요일, 12월 27, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌